The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below: ##STR00001##

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having CN, CO, CS and other bonds. ##STR00001##

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having CN, CO, CS and other bonds. ##STR00001##

A type II crystal of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole, having characteristic peaks at least around 15.1, 18.1, 22.8, 23.7, and 24.0 degrees in a diffraction angle (2) by X-ray powder diffraction, and method for producing said type II crystal.

A type II crystal of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole, having characteristic peaks at least around 15.1, 18.1, 22.8, 23.7, and 24.0 degrees in a diffraction angle (2) by X-ray powder diffraction, and method for producing said type II crystal.

A compound which is represented by a formula (IIa), ##STR00001##
wherein each of Y.sup.1 to Y.sup.8 independently represents a chemical single bond, O, S, OC(O), C(O)O, OC(O)O, NR.sup.1C(O), C(O)NR.sup.1, OC(O)NR.sup.1, NR.sup.1C(O)O, NR.sup.1C(O)NR.sup.1, ONR.sup.1, or NR.sup.1O, R.sup.1 represents a hydrogen atom or an alkyl group; each of G.sup.1 and G.sup.2 independently represents a divalent linear aliphatic group; each of Z.sup.1 and Z.sup.2 independently represents an alkenyl group; A.sup.x represents a group represented by a formula (II), ##STR00002##
wherein X represents NR.sup.2, an oxygen atom, a sulfur atom, and R.sup.2 represents a hydrogen atom or an alkyl group; D represents an alkylene group or a cycloalkanediyl group; A.sup.1 represents a trivalent aromatic group; each of A.sup.2 and A.sup.3 independently represents a divalent alicyclic hydrocarbon group; each of A.sup.4 and A.sup.5 independently represents a divalent aromatic group; Q.sup.1 represents a hydrogen atom, or an alkyl group.

A compound which is represented by a formula (IIa), ##STR00001##
wherein each of Y.sup.1 to Y.sup.8 independently represents a chemical single bond, O, S, OC(O), C(O)O, OC(O)O, NR.sup.1C(O), C(O)NR.sup.1, OC(O)NR.sup.1, NR.sup.1C(O)O, NR.sup.1C(O)NR.sup.1, ONR.sup.1, or NR.sup.1O, R.sup.1 represents a hydrogen atom or an alkyl group; each of G.sup.1 and G.sup.2 independently represents a divalent linear aliphatic group; each of Z.sup.1 and Z.sup.2 independently represents an alkenyl group; A.sup.x represents a group represented by a formula (II), ##STR00002##
wherein X represents NR.sup.2, an oxygen atom, a sulfur atom, and R.sup.2 represents a hydrogen atom or an alkyl group; D represents an alkylene group or a cycloalkanediyl group; A.sup.1 represents a trivalent aromatic group; each of A.sup.2 and A.sup.3 independently represents a divalent alicyclic hydrocarbon group; each of A.sup.4 and A.sup.5 independently represents a divalent aromatic group; Q.sup.1 represents a hydrogen atom, or an alkyl group.

The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.